Why Menopause Matters in Substance Use Disorder Prevention, Treatment, and Recovery
Impact on your practice
This is educational content from SAMHSA that informs clinical practice around women's health and substance use but does not change policy, reimbursement, or licensing requirements. It may influence continuing education offerings and clinical protocols.
Key facts
SAMHSA educational content on menopause and substance use disorder
Highlights hormonal changes affecting mood, sleep, cognition, and stress response
Targets prevention, treatment, and recovery in women
Informs clinical practice but does not mandate policy changes
Therapy Companion analysis
This SAMHSA guidance does not impose new billing codes, prior authorization requirements, or licensing mandates, but it signals a clinical competency expectation that will increasingly affect your practice operations and liability exposure. If you treat women in midlife—particularly those with substance use disorders, depression, or anxiety—you should anticipate that standard of care will evolve to include routine menopause screening and symptom assessment as part of intake and ongoing treatment planning. This is especially relevant for LCSWs, LPCs, and MFTs who work in addiction treatment settings, primary care integration models, or community mental health agencies. Your documentation should begin reflecting whether menopause status and symptoms were assessed, what the clinical relevance is to the presenting problem, and how treatment planning accounts for hormonal factors affecting mood, sleep, and stress response. Agencies receiving SAMHSA funding or operating under SAMHSA-aligned quality standards may face expectations to integrate menopause screening into their SUD protocols within the next 12–24 months, which could require staff training, revised intake forms, and updated clinical guidelines. Solo practitioners and small group practices should monitor whether your malpractice carrier or state licensing board begins citing menopause-informed care as a standard of practice, particularly in cases involving treatment failure, relapse, or inadequate symptom management in midlife women. The financial impact is indirect but real: failure to screen for and address menopause-related drivers of substance use or psychiatric symptoms increases your risk of treatment dropout, poor outcomes, and potential complaints to your licensing board.
Background
SAMHSA has historically focused substance use disorder prevention and treatment through a lens of trauma, co-occurring mental illness, and social determinants, but has largely overlooked the biological window of menopause as a distinct clinical risk factor. This guidance reflects emerging research showing that hormonal fluctuations during perimenopause and menopause can intensify anxiety, depression, insomnia, and pain—symptoms that women often self-medicate with alcohol, cannabis, or prescription opioids. The timing of this May 2026 guidance and SAMHSA's first-ever menopause symposium signals a federal pivot toward sex-specific and life-stage-specific approaches to SUD treatment. This aligns with broader healthcare trends emphasizing precision medicine and recognition that standard one-size-fits-all addiction treatment protocols may miss critical biological drivers of relapse in midlife women. For therapists, this represents a shift in how federal agencies and accrediting bodies will define competent SUD and mental health care.
What you should do
Audit your current intake and assessment forms for substance use disorder and mental health treatment. Add explicit screening questions about menopause status, perimenopause symptoms (sleep disruption, mood changes, hot flashes, anxiety), and whether the client attributes current substance use or psychiatric symptoms to hormonal changes. Document findings in every chart.
If you work in an agency or group practice, propose a clinical protocol review meeting to integrate menopause screening into your SUD and mental health treatment pathways. Request that your agency leadership monitor SAMHSA guidance and accreditation standards (CARF, NCQA, state licensing boards) for emerging menopause-informed care expectations over the next 18 months.
Pursue continuing education on menopause and its intersection with substance use, mood disorders, and sleep disturbance. SAMHSA's symposium resources and the HHS Office on Women's Health materials cited in this guidance are free and will help you speak credibly with clients and interdisciplinary teams about hormonal factors in treatment planning.
If you refer clients to or collaborate with primary care, OB/GYN, or women's health providers, establish a communication protocol to share menopause status and symptoms so that medical providers can assess whether hormone therapy or other interventions might support your behavioral health treatment. Document these referrals and follow-ups in your clinical record.
Review your malpractice insurance policy and consider whether your coverage adequately addresses SUD and mental health treatment in midlife women. If you have a high proportion of female clients aged 40–60, discuss with your carrier whether menopause-informed screening and documentation practices are expected as part of standard of care in your state or specialty.
Notable excerpts
Emerging evidence shows that going through the menopause transition can influence substance use patterns, including a woman's risk of escalating substance use and recurrence after a period of recovery. (SAMHSA, May 2026)
Despite these challenges, menopause is not usually considered in substance use disorder prevention, screening, treatment, or recovery programs. This gap highlights the need for more awareness, better guidance for providers, and care that is tailored for women in midlife. (SAMHSA, May 2026)
Strengthening collaboration between behavioral health and women's health providers is also essential. Expanding workforce training and public awareness can help ensure that providers are better equipped to recognize and address menopause-related risks. (SAMHSA, May 2026)
View full source text
Policy changes drive denial patterns
Therapy Companion tracks both: the policy shifts on this page and the denial patterns hitting your claims.
Related policy changes
[MA] H4895: Expanding access to mental health services
This bill aims to expand mental health service access in Massachusetts and has cleared committee with a favorable recommendation. Depending on final language, it could affect reimbursement rates, telehealth authorization, or insurance coverage requirements.
[TN] SB1248: AN ACT to amend Tennessee Code Annotated, Title 4; Title 8; Title 33; Title 39; Title 49; Title 53; Title 56; Title 63; Title 68 and Title 71, relative to mental health.
This comprehensive TN mental health bill touches multiple code sections and could affect licensure, scope of practice, insurance requirements, and workforce regulations. Therapists should monitor its progress closely as it moves through committee.
Advancing the Future of Behavioral Health Data Exchange
This policy direction addresses a critical pain point for therapists: the lack of integrated health data exchange with primary care and medical providers. Improved interoperability could reduce documentation burden, improve care coordination, and reduce liability from medication interactions or missed diagnoses. However, it may also increase compliance requirements and data security obligations.
Opinion: MAHA is rewriting the vocabulary of American mental health care
Federal deprescribing initiatives create new clinical and billing opportunities for therapists while potentially pressuring prescribing practices. Therapists should understand the evidence, reimbursement rules, and ethical considerations around medication tapering to protect clients and navigate changing clinical norms.